A Plus Biotechnology Co

A Plus Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of A Plus Biotechnology Co (6918.TWO) as of Oct 17, 2026 is 100.51 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 479.15 % — a change of -79.02% (lower).

FCF Conversion

100.51 %

YoY

-79.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of A Plus Biotechnology Co is 2024 100.51 % . FCF Conversion Rate (FCF/EBITDA) of A Plus Biotechnology Co was 2023 479.15 % . It decreases by -79.02% lower compared to the previous year.

The A Plus Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
124.69 TWD
Jan 1, 2020
295.46 TWD
Jan 1, 2021
-522.02 TWD
Jan 1, 2022
52.24 TWD
Jan 1, 2023
479.15 TWD
Jan 1, 2024
100.51 TWD
The A Plus Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
100.51 %-79.02%
479.15 %+817.20%
52.24 %-110.01%
-522.02 %-276.68%
295.46 %+136.95%
124.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

A Plus Biotechnology Co Stock analysis

What does A Plus Biotechnology Co do? A Plus Biotechnology Co Ltd, listed on the Taiwan Stock Exchange with ticker 6918.TWO, operates in the Health Care sector. The company is based in Taipei, Taiwan, and focuses on research, development, and manufacturing of orthopedic medical equipment. Its product portfolio includes trauma products for fracture fixation, orthopedic correction systems, artificial bone replacements, and spinal fixation devices. The company went public on January 6, 2023. Products are sold domestically and exported to mainland China, Asia, the United States, and Africa. A Plus Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about A Plus Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of A Plus Biotechnology Co is 100.51 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of A Plus Biotechnology Co changed from 479.15 % to 100.51 %, representing a -79.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) A Plus Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s A Plus Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — A Plus Biotechnology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — A Plus Biotechnology Co